You are currently viewing Samsung Teams Up with GRAIL to Launch Multi-Cancer Early Detection Test in Asia

Samsung Teams Up with GRAIL to Launch Multi-Cancer Early Detection Test in Asia

Prime Highlights

  • Samsung C&T and Samsung Electronics are partnering with GRAIL to introduce the Galleri multi-cancer early detection test in major Asian markets.
  • The collaboration marks Samsung’s strategic move into biotech and healthcare, with plans to explore AI and digital health applications.

Key Facts

  • Samsung is investing $110 million in GRAIL at $70.05 per share, with SCT acting as the exclusive distributor in the region.
  • The Galleri test detects over 50 types of cancer from a blood sample, significantly improving early detection rates with a low false-positive rate.

Background

Samsung C&T Corporation (SCT), Samsung Electronics (SEC), and U.S.-based GRAIL Inc. have partnered to introduce GRAIL’s Galleri multi-cancer early detection (MCED) test to major Asian markets. As part of the deal, Samsung C&T and Samsung Electronics will invest $110 million in GRAIL at $70.05 per share.

Samsung is taking a strategic step to expand into biotech and healthcare by partnering to launch the Galleri test in South Korea. The company may also expand this offering to Japan and Singapore. Under the agreement, SCT will act as GRAIL’s exclusive distributor in the region.

The Galleri test, developed by GRAIL, uses a simple blood sample to detect over 50 types of cancer before symptoms appear, helping doctors identify cancer at an early and more treatable stage. It is currently the only MCED test proven to double cancer detection rates when added to standard screenings, with a very low false-positive rate.

Jaywoo Kim, Executive Vice President of Life Science Business at Samsung C&T, said the partnership marks a “significant new step” in Samsung’s commitment to life sciences. Sir Harpal Kumar, President of International Business at GRAIL, said Samsung’s investment strengthens GRAIL’s financial position as it advances toward reimbursement in key markets.

In addition, Samsung Electronics and GRAIL plan to explore AI and digital health collaborations, combining Samsung’s health data platform with GRAIL’s genomic technologies to personalize healthcare for users.

The investment is expected to close in early 2026, subject to regulatory approval and final agreements.